Affimed Future Growth
Future criteria checks 2/6
Affimed's earnings are forecast to decline at 14.5% per annum while its annual revenue is expected to grow at 66.3% per year. EPS is expected to grow by 22.1% per annum.
Key information
-14.5%
Earnings growth rate
22.1%
EPS growth rate
| Biotechs earnings growth | 43.0% |
| Revenue growth rate | 66.3% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 18 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 12 | -101 | -115 | -122 | 5 |
| 12/31/2025 | 5 | -72 | -75 | -98 | 6 |
| 12/31/2024 | 1 | -64 | -8 | -59 | 5 |
| 9/30/2024 | 6 | -70 | -77 | -77 | N/A |
| 6/30/2024 | 7 | -79 | -88 | -84 | N/A |
| 3/31/2024 | 9 | -93 | -105 | -101 | N/A |
| 12/31/2023 | 14 | -106 | -114 | -110 | N/A |
| 9/30/2023 | 21 | -119 | -119 | -116 | N/A |
| 6/30/2023 | 34 | -111 | -117 | -117 | N/A |
| 3/31/2023 | 39 | -101 | -110 | -110 | N/A |
| 12/31/2022 | 43 | -86 | -106 | -105 | N/A |
| 9/30/2022 | 42 | -76 | -104 | -102 | N/A |
| 6/30/2022 | 36 | -76 | -111 | -108 | N/A |
| 3/31/2022 | 38 | -76 | -102 | -99 | N/A |
| 12/31/2021 | 42 | -58 | -90 | -87 | N/A |
| 9/30/2021 | 41 | -49 | -45 | -43 | N/A |
| 6/30/2021 | 43 | -38 | -23 | -21 | N/A |
| 3/31/2021 | 36 | -32 | -20 | -19 | N/A |
| 12/31/2020 | 29 | -41 | -20 | -19 | N/A |
| 9/30/2020 | 22 | -39 | -34 | -34 | N/A |
| 6/30/2020 | 14 | -44 | -42 | -42 | N/A |
| 3/31/2020 | 15 | -43 | -34 | -32 | N/A |
| 12/31/2019 | 21 | -32 | -31 | -29 | N/A |
| 9/30/2019 | 41 | -11 | 42 | 44 | N/A |
| 6/30/2019 | 39 | -12 | 44 | 46 | N/A |
| 3/31/2019 | 35 | -9 | 42 | 43 | N/A |
| 12/31/2018 | 24 | -19 | 49 | 49 | N/A |
| 9/30/2018 | 2 | -35 | -30 | -30 | N/A |
| 6/30/2018 | 2 | -31 | N/A | -28 | N/A |
| 3/31/2018 | 2 | -31 | N/A | -25 | N/A |
| 12/31/2017 | 2 | -30 | N/A | -26 | N/A |
| 9/30/2017 | 3 | -29 | N/A | -27 | N/A |
| 6/30/2017 | 3 | -31 | N/A | -28 | N/A |
| 3/31/2017 | 5 | -32 | N/A | -31 | N/A |
| 12/31/2016 | 6 | -32 | N/A | -32 | N/A |
| 9/30/2016 | 7 | -33 | N/A | -30 | N/A |
| 6/30/2016 | 7 | -30 | N/A | -28 | N/A |
| 3/31/2016 | 7 | -27 | N/A | -23 | N/A |
| 12/31/2015 | 8 | -20 | N/A | -19 | N/A |
| 9/30/2015 | 7 | -19 | N/A | -20 | N/A |
| 6/30/2015 | 7 | -5 | N/A | -15 | N/A |
| 3/31/2015 | 6 | 14 | N/A | -15 | N/A |
| 12/31/2014 | 4 | 0 | N/A | -11 | N/A |
| 9/30/2014 | 8 | 2 | N/A | -7 | N/A |
| 6/30/2014 | 7 | -16 | N/A | -3 | N/A |
| 3/31/2014 | 6 | -38 | N/A | -3 | N/A |
| 12/31/2013 | 6 | -26 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A28A is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: A28A is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: A28A is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: A28A's revenue (66.3% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: A28A's revenue (66.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if A28A's Return on Equity is forecast to be high in 3 years time